<DOC>
	<DOC>NCT02189304</DOC>
	<brief_summary>This is a single-center, Phase I, healthy adult subject study with a randomized, double blind, three period, three-treatment, cross-over design.</brief_summary>
	<brief_title>Pharmacokinetics and Safety Study of PT010 in Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<criteria>Informed Consent Form (ICF) prior to any study related procedures Male and female subjects 18 to 55 years, inclusive Good general health Medically acceptable contraception for women of childbearing potential and males with female partners of childbearing potential Clinical labs within normal ranges or determined to be not clinically significant by the Investigator Pregnancy, nursing female subjects, or subjects trying to conceive Clinically significant neurologic, cardiovascular, hepatic, renal, endocrinologic, pulmonary, hematological, psychiatric, or other medical illness that would interfere with participation in this study History of ECG abnormalities Cancer not in complete remission for at least 5 years Clinically significant, symptomatic prostatic hypertrophy Male subjects with a transurethral resection of the prostate or full resection of the prostate within 6 months prior to Screening Clinically significant bladder neck obstruction or urinary retention Inadequately treated glaucoma History of an allergic reaction or hypersensitivity to any drug or to any component of the formulations used in this study Subjects with preexisting anemia and/or iron deficiency</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Healthy volunteers</keyword>
</DOC>